blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2972365

EP2972365 - METHODS FOR TREATING AND DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.09.2020
Database last updated on 24.08.2024
FormerThe patent has been granted
Status updated on  18.10.2019
FormerGrant of patent is intended
Status updated on  13.06.2019
FormerExamination is in progress
Status updated on  17.08.2018
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Exagen Diagnostics, Inc.
801 University Boulevard, SE Suite 209
Albuquerque, NM 87106 / US
[2016/03]
Inventor(s)01 / DERVIEUX, Thierry
3009 Caminito Arenoso
San Diego, CA 92117 / US
02 / BARKEN, Derren
11271 Corte Playa Corona
San Diego, CA 92124-4134 / US
 [2019/47]
Former [2016/03]01 / DERVIEUX, Thierry
3009 Caminito Arenoso
San Diego, CA 92117 / US
02 / BARKEN, Derren
1261 Liberty Way
Vista, CA 92081 / US
Representative(s)Zwicker, Jörk
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
[2019/47]
Former [2016/03]Zwicker, Jörk
ZSP Patentanwälte
Partnerschaftsgesellschaft
Radlkoferstrasse 2
81373 München / DE
Application number, filing date14720772.413.03.2014
[2016/03]
WO2014US25264
Priority number, dateUS201361792284P15.03.2013         Original published format: US 201361792284 P
[2016/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014151238
Date:25.09.2014
Language:EN
[2014/39]
Type: A1 Application with search report 
No.:EP2972365
Date:20.01.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 25.09.2014 takes the place of the publication of the European patent application.
[2016/03]
Type: B1 Patent specification 
No.:EP2972365
Date:20.11.2019
Language:EN
[2019/47]
Search report(s)International search report - published on:EP25.09.2014
ClassificationIPC:G01N33/564, G01N33/68
[2019/14]
CPC:
G01N33/564 (EP,US); G01N33/6893 (US); A61K39/4636 (US);
G01N33/6854 (EP,US); G01N2333/705 (US); G01N2800/104 (EP,US);
G01N2800/24 (US); G01N2800/50 (EP,US); G01N2800/52 (EP,US);
G01N2800/56 (EP,US); G01N2800/60 (EP,US) (-)
Former IPC [2016/03]G01N33/564
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/03]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERFAHREN ZUR BEHANDLUNG UND DIAGNOSTIZIERUNG VON SYSTEMISCHEM LUPUS ERYTHEMATODES[2016/03]
English:METHODS FOR TREATING AND DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS[2016/03]
French:MÉTHODES DE TRAITEMENT ET DE DIAGNOSTIC D'UN LUPUS ÉRYTHÉMATEUX DISSÉMINÉ[2016/03]
Entry into regional phase24.08.2015National basic fee paid 
24.08.2015Designation fee(s) paid 
24.08.2015Examination fee paid 
Examination procedure24.08.2015Examination requested  [2016/03]
06.05.2016Amendment by applicant (claims and/or description)
20.08.2018Despatch of a communication from the examining division (Time limit: M06)
20.02.2019Reply to a communication from the examining division
14.06.2019Communication of intention to grant the patent
14.10.2019Fee for grant paid
14.10.2019Fee for publishing/printing paid
14.10.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  20.08.2018
Opposition(s)21.08.2020No opposition filed within time limit [2020/44]
Fees paidRenewal fee
31.03.2016Renewal fee patent year 03
27.03.2017Renewal fee patent year 04
27.03.2018Renewal fee patent year 05
27.03.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU13.03.2014
AL20.11.2019
AT20.11.2019
CY20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
IT20.11.2019
LT20.11.2019
LV20.11.2019
MC20.11.2019
MK20.11.2019
MT20.11.2019
NL20.11.2019
PL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SI20.11.2019
SK20.11.2019
SM20.11.2019
TR20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IE13.03.2020
LU13.03.2020
IS20.03.2020
BE31.03.2020
PT12.04.2020
[2022/32]
Former [2022/27]HU13.03.2014
AL20.11.2019
AT20.11.2019
CY20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
IT20.11.2019
LT20.11.2019
LV20.11.2019
MC20.11.2019
MT20.11.2019
NL20.11.2019
PL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SI20.11.2019
SK20.11.2019
SM20.11.2019
TR20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IE13.03.2020
LU13.03.2020
IS20.03.2020
BE31.03.2020
PT12.04.2020
Former [2021/10]AL20.11.2019
AT20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
IT20.11.2019
LT20.11.2019
LV20.11.2019
MC20.11.2019
NL20.11.2019
PL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SI20.11.2019
SK20.11.2019
SM20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IE13.03.2020
LU13.03.2020
IS20.03.2020
BE31.03.2020
PT12.04.2020
Former [2021/08]AL20.11.2019
AT20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
MC20.11.2019
NL20.11.2019
PL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SI20.11.2019
SK20.11.2019
SM20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IE13.03.2020
LU13.03.2020
IS20.03.2020
PT12.04.2020
Former [2021/04]AL20.11.2019
AT20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
MC20.11.2019
NL20.11.2019
PL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SI20.11.2019
SK20.11.2019
SM20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
LU13.03.2020
IS20.03.2020
PT12.04.2020
Former [2020/51]AL20.11.2019
AT20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
MC20.11.2019
NL20.11.2019
PL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SI20.11.2019
SK20.11.2019
SM20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
PT12.04.2020
Former [2020/50]AL20.11.2019
AT20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
MC20.11.2019
NL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SI20.11.2019
SK20.11.2019
SM20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
PT12.04.2020
Former [2020/37]AL20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SK20.11.2019
SM20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
PT12.04.2020
Former [2020/36]AL20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
PT12.04.2020
Former [2020/35]AL20.11.2019
CZ20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
Former [2020/34]AL20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
RS20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
Former [2020/32]AL20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
RS20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
Former [2020/26]FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
RS20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
Former [2020/24]FI20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
Former [2020/23]FI20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
Former [2020/22]FI20.11.2019
LT20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
Former [2020/21]NO20.02.2020
Cited inInternational search[Y]EP2336769  (HOFFMANN LA ROCHE [CH], et al) [Y] 1-16 * the whole document * * page 27, lines 45-46 * * claim 10 on page 29 * * figure 1 *;
 [Y]WO2012109592  (EXAGEN DIAGNOSTICS INC [US], et al) [Y] 1-16 * the whole document *;
 [Y]  - KENNETH C. KALUNIAN ET AL, "Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus", ARTHRITIS & RHEUMATISM, (20121201), vol. 64, no. 12, doi:10.1002/art.34669, ISSN 0004-3591, pages 4040 - 4047, XP055127913 [Y] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1002/art.34669
 [XP]  - CHAIM PUTTERMAN, "An Assay Panel Combining Cell Bound Complement Activation Products With Autoantibodies To Extractable Nuclear Antigens and Mutated Citrullinated Vimentin Helps With The Differential Diagnosis Of Systemic Lupus Erythematosus", ARTHRITIS & RHEUMATISM, (20131001), vol. 65, no. S10, ISSN 0004-3591, page S1078, XP055128072 [XP] 1-16 * Abstract 2525 *
 [XP]  - Chaim Putterman ET AL, "Multicenter study in the AN ASSAY PANEL COMBINING CELL-BOUND COMPLEMENT ACTIVATION PRODUCTS WITH AUTOANTIBODIES TO EXTRACTABLE NUCLEAR ANTIGENS AND MUTATED CITRULLINATED VIMENTIN HELPS WITH THE DIFFERENTIAL DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS", (20131203), URL: http://dfpcorec-p.internal.epo.org/wf/storage/1471FA326FA000134BD/originalPdf, (20140710), XP055128083 [XP] 1-16 * http://avisetest.com/images/stories/publications/sle_2013_acr_poster_final_mktg.pdf * * Poster *
by applicant   - RAHMAN A; ISENBERG DA, "Systemic lupus erythematosus", N ENGL J MED, (2008), vol. 358, no. 9, pages 929 - 939
    - HELMICK CG; FELSON DT; LAWRENCE RC; GABRIEL S; HIRSCH R; KWOH CK ET AL., "Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I", ARTHRITIS RHEUM, (2008), vol. 58, no. 1, pages 15 - 25
    - BASTIAN HM; ROSEMAN JM; MCGWIN G, JR.; ALARCON GS; FRIEDMAN AW; FESSLER BJ ET AL., "Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis", LUPUS, (2002), vol. 11, no. 3, pages 152 - 160
    - TAN EM; COHEN AS; FRIES JF; MASI AT; MCSHANE DJ; ROTHFIELD NF ET AL., "The 1982 revised criteria for the classification of systemic lupus erythematosus", ARTHRITIS RHEUM, (1982), vol. 25, no. 11, pages 1271 - 1277
    - SMITH EL; SHMERLING RH, "The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: strengths, weaknesses, and opportunities for improvement", LUPUS, (1999), vol. 8, no. 8, pages 586 - 595
    - EGNER W, "The use of laboratory tests in the diagnosis of SLE", J CLIN PATHOL, (2000), vol. 53, no. 6, pages 424 - 432
    - MANDERSON AP; BOTTO M; WALPORT MJ, "The role of complement in the development of systemic lupus erythematosus", ANNU REV IMMUNOL, (2004), vol. 22, pages 431 - 456
    - MANZI S; NAVRATIL JS; RUFFING MJ; LIU CC; DANCHENKO N; NILSON SE ET AL., "Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus", ARTHRITIS RHEUM, (2004), vol. 50, no. 11, pages 3596 - 3604
    - NAVRATIL JS; MANZI S; KAO AH; KRISHNASWAMI S; LIU CC; RUFFING MJ ET AL., "Platelet C4d is highly specific for systemic lupus erythematosus", ARTHRITIS RHEUM, (2006), vol. 54, no. 2, pages 670 - 674
    - YANG DH; CHANG DM; LAI JH; LIN FH; CHEN CH, "Usefulness of erythrocyte-bound C4d as a biomarker to predict disease activity in patients with systemic lupus erythematosus", RHEUMATOLOGY (OXFORD, (2009), vol. 48, no. 9, pages 1083 - 1087
    - LIU CC; KAO AH; HAWKINS DM; MANZI S; SATTAR A; WILSON N ET AL., "Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus", CLIN TRANSL SCI, (2009), vol. 2, no. 4, pages 300 - 308
    - KAO AH; NAVRATIL JS; RUFFING MJ; LIU CC; HAWKINS D; MC KINNON KM ET AL., "Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus", ARTHRITIS AND RHEUMATISM, (2010), vol. 62, no. 3, pages 837 - 844
    - BATAL I; LIANG K; BASTACKY S; KISS LP; MCHALE T; WILSON NL ET AL., "Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study", LUPUS, (2012), vol. 21, no. I, pages 13 - 26
    - SINGH V; MAHONEY JA; PETRI M, "Erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus", J RHEUMATOL, (2008), vol. 35, no. 10, pages 1989 - 1993
    - BANG H; EGERER K; GAULIARD A; LUTHKE K; RUDOLPH PE; FREDENHAGEN G ET AL., "Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis", ARTHRITIS RHEUM, (2007), vol. 56, no. 8, pages 2503 - 2511
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.